Biomedical Engineering Reference
In-Depth Information
93. Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol
26(8):587-596
94. Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer
strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther
75(1):69-75
95. Rayment EA, Upton Z, Shooter GK (2008) Increased matrix metalloproteinase-9 (MMP-9)
activity observed in chronic wound fluid is related to the clinical severity of the ulcer. Br
J Dermatol 158(5):951-961
96. Reijerkerk A, Kooij G, van der Pol SM, Khazen S, Dijkstra CD, de Vries HE (2006)
Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain
endothelial cells. FASEB J 20(14):2550-2552
97. Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA et al
(2006) Potent selective pyrimidinetrione-based inhibitors of MMP-13. Bioorg Med Chem
Lett 16(22):5822-5826
98. Renault MA, Losordo DW (2007) The matrix revolutions: matrix metalloproteinase vasculo-
genesis and ischemic tissue repair. Circ Res 100(6):749-750
99. Rodriguez R, Loske AM, Fernandez F, Estevez M, Vargas S, Fernandez G et al (2010) In vivo
evaluation of implant-host tissue interaction using morphology-controlled hydroxyapatite-
based biomaterials. J Biomater Sci Polym Ed 22(13):1799-1810
100. Rosenblum G, Meroueh S, Toth M, Fisher JF, Fridman R, Mobashery S et al (2007) Molecular
structures and dynamics of the stepwise activation mechanism of a matrix metalloproteinase
zymogen: challenging the cysteine switch dogma. J Am Chem Soc 129(44):13566-13574
101. Ruifrok AC, Katz RL, Johnston DA (2003) Comparison of quantification of histochemical
staining by hue-saturation-intensity (HSI) transformation and color-deconvolution. Appl
Immunohistochem Mol Morphol 11(1):85-91
102. Rush TS 3rd, Powers R (2004) The application of x-ray NMR and molecular modeling in the
design of MMP inhibitors. Curr Top Med Chem 4(12):1311-1327
103. Salmela MT, Pender SL, Karjalainen-Lindsberg ML, Puolakkainen P, Macdonald TT,
Saarialho-Kere U (2004) Collagenase-1 (MMP-1) matrilysin-1 (MMP-7) and stromelysin-2
(MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J
Gastroenterol 39(11):1095-1104
104. Salonurmi T, Parikka M, Kontusaari S, Pirila E, Munaut C, Salo T et al (2004) Overexpression
of TIMP-1 under the MMP-9 promoter interferes with wound healing in transgenic mice.
Cell Tissue Res 315(1):27-37
105. Santos MA, Marques S, Gil M, Tegoni M, Scozzafava A, Supuran CT (2003) Protease inhibi-
tors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating
succinyl hydroxamate and iminodiacetic acid hydroxamate moieties. J Enzyme Inhib Med
Chem 18(3):233-242
106. Scatena R (2000) Prinomastat a hydroxamate-based matrix metalloproteinase inhibitor.
A novel pharmacological approach for tissue remodelling-related diseases. Expert Opin
Investig Drugs 9(9):2159-2165
107. Shekaran A, Garcia AJ (2011) Extracellular matrix-mimetic adhesive biomaterials for bone
repair. J Biomed Mater Res A 96(1):261-272
108. Steward WP, Thomas AL (2000) Marimastat: the clinical development of a matrix metallo-
proteinase inhibitor. Expert Opin Investig Drugs 9(12):2913-2922
109. Stratmann B, Farr M, Tschesche H (2001) MMP-TIMP interaction depends on residue 2 in
TIMP-4. FEBS Lett 507(3):285-287
110. Sung HJ, Johnson CE, Lessner SM, Magid R, Drury DN, Galis ZS (2005) Matrix metallopro-
teinase 9 facilitates collagen remodeling and angiogenesis for vascular constructs. Tissue Eng
11(1-2):267-276
111. Takahashi H, Akiba K, Noguchi T, Ohmura T, Takahashi R, Ezure Y et al (2000) Matrix
metalloproteinase activity is enhanced during corneal wound repair in high glucose condi-
tion. Curr Eye Res 21(2):608-615
Search WWH ::
Custom Search